:

Decoding the Numbers: What is the success rate of romosozumab?

In pivotal clinical trials, romosozumab (Evenity) demonstrated a 73% relative risk reduction for new vertebral fractures versus placebo after 12 months of treatment. While this specific statistic offers insight, accurately defining `what is the success rate of romosozumab?` requires understanding the different outcomes based on fracture type and patient risk factors.